Skip to main content
CSL Behring News)

Global Newsroom

Recent News Releases

For investor-related news, see our ASX releases on our parent company's website: CSL.com.

Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
16 Nov 2020

KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa.

- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia

CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at American Heart Association Scientific Sessions 2020
10 Nov 2020

KING OF PRUSSIA, Pa.

Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
05 Nov 2020

KING OF PRUSSIA, Pa.

The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack

Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease
02 Nov 2020

KING OF PRUSSIA, Pa.

• Both US and European regulators grant special designation
• Phase 1 clinical development underway for CSL889

CSL Named as One of the World’s Best Employers
29 Oct 2020

KING OF PRUSSIA, Pa.

- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

CSL’s Broad Response to COVID-19 and Advancements Across the Company’s Strategic Scientific Platforms are the Focus of Annual R&D Day
20 Oct 2020

MELBOURNE, AU and KING OF PRUSSIA, PA

• Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential preventative or treatment options in the fight against COVID-19

• Advancements across Cell and Gene Therapy, Recombinant Technology, Plasma Fractionation and Cell and Egg-Based Vaccines scientific platforms all spotlighted including internal progression, acquisitions and alliances

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
08 Oct 2020

Osaka, JAPAN and King of Prussia, Pa., USA

• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
• The CoVIg-19 Plasma Alliance urges anyone who has recovered from COVID-19 to consider donating plasma. To learn more, please visit TheFightIsInUs.org

CSL Behring’s Global Role in Battling COVID-19
08 Oct 2020

Here is how CSL Behring is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

COVID-19 Update
08 Oct 2020

CSL continues to provide medicines to patients around the world.

U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
28 Sep 2020

KING OF PRUSSIA, PA
HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older

CSL Behring Continues to Support Alpha 1 Community, Presents Exciting, New Drug Development Projects at 30th Anniversary of the European Respiratory Society International Congress
04 Sep 2020

MARBURG, Germany

- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness

At White House Roundtable, Plasma Industry Leader & CSL CEO Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19
30 Jul 2020

• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.

• The more convalescent plasma the industry collects – and the more quickly it does so – directly influences the timeline to deliver a potential hyperimmune globulin for COVID-19.

• The clinical trial, sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in which the CoVIg-19 Plasma Alliance will participate is expected to begin soon.

CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress
09 Jul 2020

KING OF PRUSSIA, Pa.

• Five coagulation researchers named this year’s recipients
• Professor Heimburger Awards and ISTH Virtual Congress sponsorship showcase CSL Behring’s commitment to hematology research

In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress
06 Jul 2020

KING OF PRUSSIA, Pa.

- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
- CSL Behring now evaluating 5 approaches to preventing and treating COVID-19

CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
24 Jun 2020

KING of PRUSSIA, Pa.

• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
• CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B

CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit
12 Jun 2020

King of Prussia, Pa

Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020

CSL Behring to Acquire Biotech Company Vitaeris
08 Jun 2020

KING OF PRUSSIA, Pa

• Builds on CSL Behring’s promise and commitment to the transplant community
• Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio

CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema
08 Jun 2020

HATTERSHEIM, Germany

Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation

Resources for Media

Fact Sheet           

At-a glance Facts and Figures About CSL Behring    

Brand Center           

Logos, Design Guidelines and more. (Registration required)

Brochure           
See how we are Driven by Our Promise in our 16-page Corporate Brochure.                        

CSL Behring Media Contacts

Natalie de Vane

Corporate & Immunology Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4468

Jennifer Purdue

Hematology, Respiratory and Transplant Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4802

Faraz Kermani

Corporate Inquiries, Europe
Hattersheim am Main, Hesse, Germany
Phone: +49 69 305 17169

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 151 58438860

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

CSL Plasma:
For any CSL Plasma corporate or donation inquiries, please refer to the CSL Plasma website for more information.

Archived News Releases